BillionToOne, Inc.

NASDAQ:BLLN

Medical - Diagnostics & Research

Healthcare
$91.54 +0.84%

+$0.84 today

Market cap
$4.37B
Beta
0.90
P/E (TTM)
182.6
EPS (TTM)
$0.55
52W Low $61.96High $138.70

Volume 1.44M

Average 0.59M

BLLN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

BillionToOne, Inc.NASDAQ: BLLN

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation grows 200.7% year over year

Q2 FY2026 stock-based compensation of $8.22M rose 200.7% year over year. Sequentially, it rose 26.2% from the prior quarter.

Context

  • Stock-based compensation amounted to 5.2% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$8.22M+26.2% QoQ
Last fiscal yearDec 2025
$15.92M+90.3% YoY
LTMJun 2026
$25.54M— YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+200.7%——
1 year+90.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
15.92M USD
Year-over-year change
+90.3%
2-year CAGR
+81.1%

Stock-Based Compensation vs competitors

How BLLN compares with its peers on the latest reported figures

  • BLLN's LTM Jun 2026 stock-based compensation of $25.54M is the 8th largest of the 9 companies compared; the peer median is $33.95M.
  • Stock-based compensation amounts to 6.4% of revenue for BLLN, versus a peer median of 8.2%.
BLLN Competitors Peer median
Stock-Based Compensation for BLLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$381.42M +21.6%+32.5%14.1%
GHGuardant Health, Inc.LTM Sep 2026$210.96M +32.4%+20.6%16.5%
VCYTVeracyte, Inc.LTM Jun 2026$48.51M +20.3%+17.7%8.6%
WGSGeneDx Holdings Corp.LTM Jun 2026$35.7M +95.3%-8.5%7.9%
MYGNMyriad Genetics, Inc.LTM Mar 2026$32.2M -31.9%-2.6%3.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$29.03M -33.3%+6.6%9.1%
NEONeoGenomics, Inc.LTM Jun 2026$28.16M -29.2%+18.8%3.7%
BLLNBillionToOne, Inc.LTM Jun 2026$25.54M ——6.4%
GRALGRAIL, Inc.LTM Jun 2026$5.97M -90.3%-8.4%3.6%
Peer median (excluding BLLN) $33.95M-4.4%+12.2%8.2%

Competitors are the stored peer set for BLLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(82.68M)(41.57M)2.92M
Depreciation & Amortization6.46M11.69M11.91M
Deferred Income Tax000
Stock-Based Compensation4.85M8.36M15.92M
Change in Working Capital3.79M(16.77M)(22.05M)
Accounts Receivables(2.59M)(15.62M)(16.91M)
Inventory(1.41M)(1.54M)(8.81M)
Accounts Payables151K877K1.78M
Other Working Capital7.64M(489K)1.89M
Other Non-Cash Items13.9M(3.09M)15.91M
Operating Cash Flow(53.67M)(41.38M)24.6M
Capital Expenditures(6.17M)(5.4M)(8.88M)
Acquisitions (Net)000
Purchases of Investments000
Sales of Investments90M00
Other Investing Activities(988K)(31K)0
Investing Cash Flow82.84M(5.43M)(8.92M)
Debt Repayment12.96M10.48M(1.73M)
Common Stock Issued444K131.08M290.55M
Common Stock Repurchased0(546K)0
Dividends Paid000
Other Financing Activities000
Financing Cash Flow13.41M141.02M288.83M
Effect of Forex Changes54.7M00
Net Change in Cash97.27M94.21M304.5M
Free Cash Flow(59.85M)(46.78M)15.71M

BillionToOne, Inc.

NASDAQ:BLLN

Intrinsic Alpha fair value

Locked

Current Price

$91.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.